Smartleaf Asset Management’s Krystal Biotech KRYS Stock Holding History

Smartleaf Asset Management’s Portfolio KRYS Stock Details KRYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$76.1K	Sell	308 -302	-50%	-$80.4K	﹤0.01%	1248
2025 Q4	$151K	Buy	610 +188	+45%	+$39.6K	0.01%	955
2025 Q3	$74.6K	Buy	422 +212	+101%	+$31.7K	﹤0.01%	1225
2025 Q2	$29.2K	Sell	210 -105	-33%	-$15.4K	﹤0.01%	1399
2025 Q1	$57.9K	Buy	315 +177	+128%	+$29.8K	0.01%	1076
2024 Q4	$22.1K	Buy	138 +54	+64%	+$9.58K	﹤0.01%	1593
2024 Q3	$14.9K	Buy	84 +66	+367%	+$12.7K	﹤0.01%	1520
2024 Q2	$3.29K	Buy	18 +14	+350%	+$2.35K	﹤0.01%	2004
2024 Q1	$708	Buy	+4	New	+$556	﹤0.01%	1689

Other funds holding KRYS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Smartleaf Asset Management's KRYS Position: Q1 2026 in Review

Smartleaf Asset Management reduced its Krystal Biotech (KRYS) stake by 50% in Q1 2026, selling an estimated $80.4K and leaving 308 shares worth $76.1K. The position accounts for ﹤0.01% of the portfolio, ranked #1248.

Smartleaf Asset Management first reported a position in KRYS in Q1 2024 and has held it in 9 quarters since. The position peaked at $151K in Q4 2025. 367 funds tracked by Wall St. Rank hold KRYS as of Q1 2026.

Smartleaf Asset Management held 308 shares of Krystal Biotech worth $76.1K as of Q1 2026.
Smartleaf Asset Management sold 302 Krystal Biotech shares in Q1 2026, an estimated $80.4K.
Krystal Biotech made up ﹤0.01% of Smartleaf Asset Management's portfolio in Q1 2026, its #1248 holding.
Smartleaf Asset Management first reported a position in Krystal Biotech in Q1 2024 and has held it in 9 quarters since.
Smartleaf Asset Management's Krystal Biotech position peaked at $151K in Q4 2025.
367 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2026.

Based on Smartleaf Asset Management's 13F filing for Q1 2026, filed 15 May 2026.